IGF-1 DES
IGF-1 DES (1-3) (DES(1-3) IGF-1)
IGF-1 DES (DES(1-3) IGF-1) is a truncated form of insulin-like growth factor-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu), which renders it approximately 10-fold more potent than standard IGF-1 due to negligible binding affinity to IGF-binding proteins (IGFBPs). It is primarily used in research contexts for its highly localized anabolic, muscle hypertrophy, and tissue repair effects, and is investigated by bodybuilders and biohackers for site-specific muscle growth when administered via intramuscular injection.
Mechanism of Action
DES IGF-1 binds directly to the IGF-1 receptor (IGF-1R) and activates downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, promoting protein synthesis, myoblast proliferation, satellite cell activation, and anti-apoptotic effects. Because it lacks binding affinity for IGFBPs (particularly IGFBP-3), it remains in its free, biologically active form at the injection site far longer than full-length IGF-1, enabling potent and localized anabolic signaling. Unlike full-length IGF-1, its reduced systemic distribution limits whole-body hypoglycemic risk, though local effects are significantly amplified.
Evidence by Health Goal(13 goals)
Dosing Protocols
Immediately post-workout, administered intramuscularly into the target muscle group
Cycle: 4-6 weeks on, 4-6 weeks off
Intramuscular injection into the specific muscle targeted for growth is preferred to exploit local activity. Most research protocols use 20-50mcg per injection site. Total daily dose should not exceed 100mcg. Reconstitute lyophilized powder with bacteriostatic water; store at 2-8°C after reconstitution.
Safety & Side Effects
IGF-1 DES has a more localized safety profile than full-length IGF-1 or IGF-1 LR3, but carries meaningful risks including hypoglycemia, mitogenic activity that could theoretically accelerate growth of undetected malignancies, and unknown long-term effects in humans. It is an unregulated research chemical in most jurisdictions, not approved for human use by the FDA or EMA, and should be used only in controlled research settings.
Possible Side Effects
- !Localized hypoglycemia near injection site, particularly when injected intramuscularly near vascular tissue
- !Systemic hypoglycemia (less common than IGF-1 LR3 but possible at higher doses)
- !Injection site pain, redness, or swelling
- !Headache and lightheadedness associated with blood glucose fluctuations
- !Potential promotion of pre-existing neoplastic cell proliferation due to IGF-1R activation
- !Jaw pain or joint discomfort (acromegalic symptoms) with prolonged high-dose use
- !Peripheral edema and water retention at high doses
Interactions
- -Insulin and insulin secretagogues: additive hypoglycemic risk; concurrent use substantially increases hypoglycemia danger
- -Growth hormone (GH): synergistic anabolic effects but also amplified hypoglycemia and mitogenic risks when combined
- -Antidiabetic medications (metformin, sulfonylureas): enhanced glucose-lowering effect may cause severe hypoglycemia
- -Corticosteroids: may blunt IGF-1R signaling and reduce efficacy of DES IGF-1
- -Anticancer therapies: IGF-1R activation may theoretically antagonize certain oncology treatments targeting the IGF/insulin axis
Cost & Where to Buy
Typically sold in lyophilized vials of 100-1000mcg from research peptide vendors at $20-60 per vial; monthly cost based on 50mcg/day protocol. Price varies significantly by vendor purity, vial size, and quantity purchased. No pharmaceutical-grade human product is commercially available.
Search on Amazon